Aptevo Therapeutics Inc., a clinical-stage biotechnology company specializing in immune-oncology therapeutics, has announced an $8 million offering priced at-the-market under Nasdaq rules. The company has entered into securities purchase agreements with healthcare-focused and institutional investors to purchase 2,465,000 shares of its common stock or pre-funded warrants, along with warrants to buy up to 12,325,000 additional shares. Each share is priced at $3.25 and comes with five warrants for additional shares at the same price, exercisable upon stockholder approval and expiring five years afterward. The offering is expected to close shortly, with Roth Capital Partners serving as the placement agent. Aptevo plans to utilize the net proceeds for clinical development, working capital, and general corporate needs.